Clinical Trial Update: Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial to assess adverse events and changes in disease activity when adding ABBV-932 to antidepressant therapy in adults with generalized anxi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• ABBV-932

Snippet

Sponsor: AbbVie | Conditions: Generalized Anxiety Disorder (GAD) | Phase 2 | Status: RECRUITING